Cladribine as a therapeutic option in multiple sclerosis

Cladribine as a therapeutic option in multiple sclerosis

Copyright © 2011. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 142(2012), 1 vom: 15. Jan., Seite 68-75
1. Verfasser: Warnke, Clemens (VerfasserIn)
Weitere Verfasser: Leussink, Verena I, Goebels, Norbert, Aktas, Orhan, Boyko, Alexey, Kieseier, Bernd C, Hartung, Hans-Peter
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2012
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Review Immunosuppressive Agents Cladribine 47M74X9YT5
Beschreibung
Zusammenfassung:Copyright © 2011. Published by Elsevier Inc.
There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug
Beschreibung:Date Completed 06.03.2012
Date Revised 21.11.2013
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2011.05.009